Helmerich & Payne shares should be bought on weakness, says BMO Capital After Helmerich & Payne reported lower than expected operating EPS, BMO Capital thinks the subsequent sell-off was overdone. The firm thinks the stock is undervalued, given the company's outsized new build orders and rising international land activity. It keeps an Outperform rating on the stock.
Helmerich & Payne downgraded to Equal Weight at Stephens As previously reported, Stephens downgraded Helmerich & Payne to Equal Weight from Overweight citing the firm's outlook for reduced U.S. onshore spending. The firm said it remain convicted in H&P as a core holding, but that its "hard to get excited" about shares at these levels. Stephens lowered its price target on Helmerich & Payne to $74 from $79.